Christopher W Guske

Mr. Christopher W Guske

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Justin MillerJustin Miller
Justin Miller
JJJeffrey Samuel Johnson
Jeffrey Samuel Johnson
CGChristopher W Guske
Christopher W Guske
GMGowtam Mannam
Gowtam Mannam
FHFiras Hatoum
Firas Hatoum
Jad ChahoudJad Chahoud
Jad Chahoud
Renal cell carcinoma (RCC) is a heterogeneous disease that represents the most common type of kidney cancer. The classification of RCC is primarily based on distinct morphological and molecular characteristics, with two broad categories: clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC). Clear cell RCC is the predominant subtype, representing about 70–80% of all RCC cases, while non-clear cell subtypes collectively make up the remaining 20–30%. Non-clear cell RCC encompasses many histopathological variants, each with unique biological and clinical characteristics. Additionally, any RCC subtype can undergo sarcomatoid dedifferentiation, which is associated with poor prognosis and rapid disease progression. Recent advances in molecular profiling have also led to the identification of molecularly defined variants, further highlighting the complexity of this disease. While immunotherapy has shown efficacy in some RCC variants and subpopulations, significant gaps remain in the treatment of rare subtypes. This review explores the outcomes of immunotherapy across RCC subtypes, including rare variants, and highlights opportunities for improving care through novel therapies, biomarker-driven approaches, and inclusive clinical trial designs.


16 July 2025 in European Urology Oncology
Verified
Journal Article
Closed access
CGChristopher W Guske
Christopher W Guske
SJSeyed Behzad Jazayeri
Seyed Behzad Jazayeri
CHChristian Harrs
Christian Harrs
NRNagashree Rao
Nagashree Rao
FDFacundo Davaro
Facundo Davaro
RLRoger Li
Roger Li

29 July 2025 in Kidney Cancer
Verified
Journal Article
Open access
MHMitchell T Hayes
Mitchell T Hayes
JLJose Laborde
Jose Laborde
ASAlex C Soupir
Alex C Soupir
ABAnders Berglund
Anders Berglund
JTJamie K Teer
Jamie K Teer
BMBrandon J Manley
Brandon J Manley
Background: Papillary renal cell carcinoma (pRCC) is the second most common kidney cancer subtype, yet our understanding of its tumor immune microenvironment (TIME) remains limited. Objective: We utilized multiplex immunofluorescence (mIF) and spatial transcriptomics (ST) to evaluate immune cell architecture in pRCC contrasted with clear cell RCC (ccRCC). Methods: Localized RCC tumors (16 pRCC, 70 ccRCC) underwent mIF using markers for T cells, B cells, and tumor-associated macrophages (TAMs). Spatial data in both tumor and stromal compartments of the TIME were collected. A post hoc recurrence free survival analysis (RFS) was performed using Cox proportional hazard models. Single-cell ST was performed on a subset of samples, utilizing probes against 960 transcripts. Cell density, cell spatial clustering, and spatially varying gene expression were analyzed. Results: Immune cell density was statistically lower in pRCC amongst functional CD8T cells, while cell clustering was higher amongst M2-like macrophages. Using ST, two genes ( CCL18 , GPNMB ) were enriched in clustered M2-like macrophages in pRCC (FDR < 0.001) and are known markers of lipid-associated TAMs (LAMs). Conclusion: Compared to ccRCC, pRCC has greater M2-like macrophage clustering. Using ST, M2-like macrophage clustering corresponds with lipid associated TAMs (LAMs), and therapeutics against this myeloid subset are currently being tested in pRCC.

23 January 2025 in Cancer Control
Verified
Journal Article
Open access
CGChristopher W Guske
Christopher W Guske
NINusheen Immen
Nusheen Immen
DCDevon Conant
Devon Conant
JLJose Laborde
Jose Laborde
JLJoshua Linscott
Joshua Linscott
SFSeth Felder
Seth Felder
Introduction: Total pelvic exenteration (TPE) for clinical T4b colorectal cancer (CRC) is associated with significant morbidity. Short (0-30 days)- and intermediate (31-90 days)-term temporal analysis of complication onset is not well described, yet needed, to better counsel patients considering TPE. Methods: A retrospective cohort study of consecutive patients with primary or recurrent clinical T4b pelvic CRC undergoing open TPE between 2014 and 2023 was conducted. Clinicopathologic variables were collected for each patient. Postoperative morbidity was classified according to the Clavien-Dindo (CD) grade system and stratified by time of onset within 90 days of surgery. Pearson’s Chi-square test, Fisher’s Exact test, and the Mann-Whitney U test were used to compare primary vs recurrent patient groups, and logistic regression assessed predictors of postoperative morbidity. Statistical analysis was performed using R with two-sided significance set at <0.05. Results: Twenty-seven patients were identified of which 24 (88.9%) were male with a median age of 60.4 years (interquartile range [IQR]: 56.3-70.5). Seventeen (63.0%) patients had primary disease and 10 (37.0%) had recurrent CRC. Twenty-three (85.2%) patients experienced at least one complication within 90 days of surgery, but no mortality was observed. Ten (37.0%) patients experienced a CD ≥ 3 event, of which 40% took place beyond 30 days. The most common complication overall was anemia requiring transfusion, while the most common major complication was pelvic abscess. No clinicopathologic variables analyzed were predictive of major postoperative complication within 90 days of TPE. Conclusion: TPE for clinical T4b CRC carries a high risk of postoperative morbidity in both the short- and intermediate-term after surgery, with a significant proportion of complications occurring after 30 days. Given the magnitude of operation, an extended recovery with high risk for complications is common. Although a single-center series, this annotated postoperative complication profile may assist patients and clinicians when reviewing informed consent for TPE.